Skip to content
Jeena Sikho Lifecare logo

Jeena Sikho Lifecare

JSLL NSE
₹336.65 −7.05 (−2.05%)
P/E
17.69
View as Markdown
MCP
Close 4 Nov 2026 ₹336.65 −448.55 −57.1% 1Y
Start ₹785.20

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
64.40%
Debt to Equity
0.27
EPS (TTM)
₹19.03
Book Value
₹37.57
Market Cap
—
P/E (TTM)
17.69
P/B
8.96
ROE
61.40%
Dividend Yield
1.31%
EBITDA
₹358 Cr
52W High
₹835.00
52W Low
₹326.00
Day Range
₹326.00 – ₹345.55
Volume
13,21,310

Peer Comparison

Consumer Discretionary › Healthcare › Pharmaceuticals › Wellness

Jeena Sikho Lifecare peer comparison
Jeena Sikho Lifecare (this company)
₹336.6517.69₹4,227 Cr8.961.31%61.40%64.40%₹851 Cr₹237 Cr
Kaya
₹308.80—₹471 Cr—0.00%—−45.60%₹235 Cr−₹97 Cr
Lloyds Luxuries
₹65.00—₹154 Cr4.660.00%−4.31%−4.27%——
Quanto Agroworld
₹59.08—₹103 Cr1.590.00%28.10%25.60%——
Median 4 companies₹186.9017.69₹312 Cr4.660.00%28.10%10.67%₹543 Cr₹70 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

62 Good

Data confidence 100/100

Category scores

Quality
89
Strong
Returns, margins, earnings quality 22% weight
Valuation
62
Good
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
81
Strong
Solvency, leverage, coverage 9% weight
Momentum
15
Poor
Trend strength, vol-adjusted 12% weight
Ownership
46
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

6
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 84.5% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 49.1%
  • Company has been maintaining a healthy dividend payout of 19.8%
  • Debtor days have improved from 48.1 to 31.8 days.
  • Company's working capital requirements have reduced from 32.2 days to 11.0 days

Weaknesses

2
  • Stock is trading at 10.3 times its book value
  • Promoter holding has decreased over last 3 years: -4.29%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1135
OscillatorsStrong Bullish135
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
24.31
Bullish
MACD (12,26,9)
−33.79
Bullish
SMA (50)
447.95
Bearish
SMA (200)
581.80
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+42.57%
3Y+57.76%
1Y+70.79%
TTM+56.91%

Net profit

Net profit growth by window
5Y+85.90%
3Y+86.91%
1Y+177.50%
TTM+104.31%

Operating cash flow

Operating cash flow growth by window
5Y+70.85%
3Y+148.86%
1Y+211.90%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+31.32 pp
3Y+21.27 pp
1Y+13.76 pp
TTM+6.70 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹106 Cr
Mar 2020₹94.00 Cr
Mar 2021₹136 Cr
Mar 2022₹146 Cr
Mar 2023₹204 Cr
Mar 2024₹324 Cr
Mar 2025₹469 Cr
Mar 2026₹801 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹6.00 Cr
Mar 2020₹6.00 Cr
Mar 2021₹10.00 Cr
Mar 2022₹11.00 Cr
Mar 2023₹34.00 Cr
Mar 2024₹69.00 Cr
Mar 2025₹80.00 Cr
Mar 2026₹222 Cr

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Jeena Sikho Lifecare Ltd is a Rs 7,181 Cr market cap company that has delivered exceptional profit growth of 85% CAGR over 5 years and TTM sales growth of 71%, while trading at a P/B of 15.3x and P/E of 32.3x.

Bull Case 8
  • Compounded profit growth of 85% CAGR over 5 years demonstrates sustained earnings momentum far exceeding sector averages
  • TTM sales growth of 71% indicates strong revenue acceleration and expanding market reach
  • 3-year ROE of 50% and last year ROE of 60% reflect exceptional capital efficiency and profitability
  • Debtor days improved from 51.4 to 31.8 days, signaling better working capital management and faster cash conversion
  • 3-year compounded sales CAGR of 58% shows consistent top-line scaling over a meaningful period
  • Healthy dividend payout ratio of 19.1% with 0.19% yield shows willingness to return capital to shareholders even during high-growth phase
  • TTM profit growth of 152% suggests a significant step-up in earnings trajectory in the most recent period
  • Stock CAGR of 116% over 3 years reflects market recognition of the company's growth execution
Bear Case 8
  • P/B ratio of 15.3x is extremely elevated, pricing in substantial future growth and leaving little room for disappointment
  • P/E of 32.3x is a premium multiple that requires continued high earnings growth to justify current valuation
  • No 52-week high/low data available (reported as 0), limiting ability to assess recent price volatility and technical support levels
  • Absence of reported debt-to-equity ratio creates uncertainty around the company's leverage and financial risk profile
  • Limited long-term track record with no 10-year sales or profit CAGR data available, making it difficult to assess durability through full market cycles
  • Dividend yield of only 0.19% provides negligible income cushion for investors if growth decelerates
  • At Rs 7,181 Cr market cap with 85% profit CAGR, sustaining such growth rates becomes mathematically harder as the base expands, creating mean-reversion risk
  • Consumer discretionary sector classification exposes the company to demand cyclicality and discretionary spending slowdowns during economic downturns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: JSLL is in aggressive expansion mode, opening new hospitals and clinics across UP (Mathura, Lucknow, Ayodhya) while investing in Ayurveda research via a Chandigarh institute. No material headwinds are visible; the ₹9.05 Cr asset sale with lease-back provides liquidity without disrupting operations. The expansion trend is clearly accelerating with multiple facilities targeting August 2026 commencement, though investors should monitor execution risk across simultaneous projects.

Positives 4
  • Research institute MoU signed Jun 15

    JSLL signed a five-year MoU to establish a research institute in Chandigarh focused on Ayurveda and integrative healthcare, strengthening R&D capabilities.

  • New 160+ bed Lucknow hospital Jun 12

    Proposed 160+ bed hospital in Lucknow spanning ~1.25 lakh sq. ft. with operations commencing August 2026, funded internally at ~₹3 Cr investment.

  • 100-bed Mathura hospital operational Jun 10

    Sanskriti Ayurvedic P.G. Medical College & Hospital commenced operations on June 10 with 100 beds across 60,000 sq. ft. and OPD capacity of 8.

Neutral 3
  • Land sale with lease-back ₹9.05 Cr Jun 19

    Board approved sale of Punjab land and building to VSB Enterprises for ₹9.05 Cr; operations continue via lease-back arrangement.

  • GIA conference participation Jun 23 Jun 17

    Management to attend GIA Flagship Conference on June 23, 2026 in Mumbai for a physical group meeting with analysts.

  • Virtual investor meet Jun 12 Jun 9

    Investor/analyst meet held on June 12, 2026, organized virtually by Choice Institutional Equities.

Quarterly Results

₹ Cr
JSLL quarterly results, ₹ crore
Particulars Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
100
114
116
139
174
190
222
216
224
Expenses
75
74
86
93
96
98
121
138
132
Operating Profit
25
40
30
46
79
92
101
78
92
OPM %
25%
35%
26%
33%
45%
48%
45%
36%
41%
Other Income
3
3
0
0
1
1
3
4
14
Interest
1
2
4
3
2
4
3
4
3
Depreciation
5
6
8
9
10
10
11
16
15
PBT
21
35
18
34
69
79
89
62
87
Tax %
23%
25%
26%
25%
25%
25%
25%
26%
25%
Net Profit
16
27
13
25
51
59
67
45
66
EPS (₹)
1.3
2.14
1.06
2.04
4.13
4.73
5.37
3.65
5.28

Profit & Loss

₹ Cr
JSLL profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
106
94
136
146
204
324
469
801
851
Expenses
95
84
119
128
158
231
328
450
488
Operating Profit
11
11
17
18
46
93
141
351
363
OPM %
10%
11%
13%
12%
23%
29%
30%
44%
43%
Other Income
0
1
1
1
2
6
6.41
8.66
22
Interest
1
2
1
1
1
0
11
12.83
15
Depreciation
1
2
2
3
3
5
29
48
53
PBT
8
8
14
15
45
94
108
298
317
Tax %
28%
26%
27%
26%
24%
26%
26%
25%
—
Net Profit
6
6
10
11
34
69
80
222
237
EPS (₹)
66.67
63.67
93.55
1.24
2.71
5.57
6.43
17.87
19.03
Div. Payout %
0%
0%
0%
0%
8%
17%
17%
25%
—

Balance Sheet

₹ Cr
JSLL balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.1
0.1
0.1
10
14
25
25
25
Reserves
8
14
24
26
112
167
231
443
Borrowings
16
12
12
7
1
1
117
127
Other Liabilities
12
12
13
18
24
28
46
78
Total Liabilities
36
38
49
62
151
221
419
673
Fixed Assets
13
17
23
28
60
67
253
292
CWIP
0
0
0
5
1
4
13
3
Investments
0
0
0
0
5
4
4
110
Other Assets
23
21
26
28
86
146
149
269
Total Assets
36
38
49
62
151
221
419
673

Cash Flow

₹ Cr
JSLL cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1
12
18
17
17
37
84
262
Investing
−11
−6
−8
−20
−57
−18
−64
−211
Financing
7
−5
−2
−5
48
−3
−22
−59
Net Cash Flow
−2
1
8
−7
8
15
−2
−8
Free Cash Flow
−10
6
9
−1
−13
23
45
231
CFO/OP
35
130
125
118
55
66
84
96

Ratios

JSLL financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
15
17
9
22
40
46
66
32
Inventory Days
204
315
208
136
87
121
78
80
Days Payable
125
168
73
109
129
75
106
86
Cash Conversion Cycle
94
163
143
49
−2
92
38
26
Working Capital Days
−16
−15
−19
−11
29
58
28
11
ROCE %
—
38%
50%
39%
53%
58%
41%
64%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jeena Sikho Lifecare insights

62 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 63.67%
  • Public 20.97%
  • Others 10.33%
  • FIIs 4.50%
  • DIIs 0.53%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Jeena Sikho Lifecare

What does Jeena Sikho Lifecare Ltd do?
Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.
Where is Jeena Sikho Lifecare Ltd (JSLL) listed?
Jeena Sikho Lifecare Ltd trades as JSLL on the NSE and under code 544476 on the BSE.
Which sector does Jeena Sikho Lifecare Ltd belong to?
Jeena Sikho Lifecare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd trades at a PE ratio of 17.69 as of 4 Nov 2026, on earnings per share of ₹19.03, against a book value of ₹37.57 per share.
What is the 52-week high and low of Jeena Sikho Lifecare Ltd?
Over the last 52 weeks Jeena Sikho Lifecare Ltd has traded between ₹326 and ₹835 as of 4 Nov 2026.
Does Jeena Sikho Lifecare Ltd pay dividends?
Jeena Sikho Lifecare Ltd has a dividend yield of 1.31%.
What is the Return on Equity (ROE) of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd reported a return on equity of 61.40%. Its debt-to-equity ratio is 0.27.

Company Information

Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.

Website jeenasikho.com
Listed 11 Aug 2025
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JSLL.md for Jeena Sikho Lifecare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month